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E-mail addresses: segade@dental.upenn.edu, fernaArterial Tortuosity Syndrome (ATS) is a heritable disease characterized by twisting and lengthening
of the major arteries, hypermobility of the joints, and laxity of skin. ATS is caused by mutations in
SLC2A10, encoding Glucose Transporter 10 (GLUT10). The current model of ATS holds that loss of
GLUT10 at the nuclear periphery induces a glucose-dependent increase in Transforming Growth
Factor-b (TGFb) that stimulates vessel wall cell proliferation. Instead, we propose that GLUT10 trans-
ports ascorbate, a cofactor for collagen and elastin hydroxylases, into the secretory pathway. In ATS,
loss of GLUT10 results in defective collagen and/or elastin. TGFb activation represents a secondary
response to a defective extracellular matrix.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Arterial tortuosity syndrome
The maintenance of a laminar blood ﬂow regime depends on
the minimization of vessel curvature in order to avoid differential
shear stress on the vessel walls. Alteration of the anatomically cor-
rect curvature can be the cause, or result from, a number of Cardio-
vascular (CV) problems. Tortuosity of the arteries results from the
abnormal elongation of a vessel in response to persistent growth
stimuli [1]. Since the arterial termini are anatomically ﬁxed,
longitudinal growth forces the vessel to curve and become tortu-
ous [1]. Tortuosity is likely to create disturbances in the blood ﬂow
and increased wall shear stress [2], which predispose the vessel to
atherosclerosis [3] and cerebrovascular stroke [4]. Increased tortu-
osity is seen in aging, induced by the loss of stiffness of the vessel
wall [5], and in chronic hypertension [6].
Arterial Tortuosity Syndrome (ATS, OMIM 208050) is a rare and
heritable form of extreme arterial tortuosity with an autosomal
recessive form of transmission, caused by defects in SLC2A10 [7],
the gene coding for the Glucose Transporter 10 (GLUT10). ATS pa-
tients present generalized tortuosity and elongation of the major
thoracic, abdominal and cranial arteries, and the pathology may
also include aneurysms, dilatations and stenosis of the arteries;
and ventricular hypertrophy (OMIM 208050). Histologically, vessel
walls show fragmentation of the internal elastic lamina [8], disrup-chemical Societies. Published by E
y, School of Dental Medicine,
lphia, PA 19104, USA. Fax: +1
ndo.segade@gmail.comtion of the elastic ﬁbers of the media [9], disorganization of the
ﬁbronectin Extracellular Matrix (ECM) and actin cytoskeleton
[10]. Non-vascular clinical features include laxity and softness of
the skin and subcutaneous tissues, hypermobility of the joints, gas-
tric and inguinal hernias, intestine elongation, and rectal prolapse
[4,9–14]. Bone and cartilage may also show defects, including soft
nasal cartilage [14], micrognathia [7,13,14], and elongated facial
features [7,12,14]. Signiﬁcantly for a genetic defect in a putative
sugar transporter, the only study which examined metabolic
parameters found no evidence of problems in glucose homeostasis
[11]. ATS does not present with a unique set of clinical features,
sharing instead etiologies with a number of genetic syndromes
which, although caused by mutations in unrelated genes, form a
‘‘continuum” of pathologies with abnormal vessel wall architecture
and defects in the extracellular matrix [15].
2. The arterial tortuosity protein: glucose transporter 10
(GLUT10)
Cells require a constant supply of monosaccharides, whether
for energy supply and storage (e.g. glucose and fructose), as pre-
cursors of complex carbohydrates (e.g. glucosamine for post-trans-
lational modiﬁcation of proteins), or as precursors of intracellular
messengers in signal transduction pathways (e.g. myo-inositol).
However, the plasma membrane is impermeable to the hydro-
philic sugars. Two families of specialized transporter molecules
translocate sugars across membranes: the SGLT Na+-sugar cotrans-
porters, and the GLUT facilitative transporters [16]. The 14
members of the GLUT family of facilitative transporters use thelsevier B.V. All rights reserved.
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the external and internal faces of a membrane to facilitate translo-
cation [16]. As passive carriers, GLUTs do not require an energy
supply although in some cases translocation of the ligand may
be coupled to the symport of H+. Structurally, GLUTs adopt a con-
formation in which their 12 hydrophobic regions span the mem-
brane in antiparallel domains joined by hydrophilic loops of
variable length. Two long loops that may act as ligand binding sites
or signaling domains face opposite sites of the membrane. Both the
N- and C-termini are located on the endofacial side of the mem-
brane [16]. The current functional model of GLUT-mediated trans-
port hypothesizes that the transmembrane domains create a
central pore through which the ligand is translocated across the
membrane within an aqueous environment [16]. Critical residues
for the function of the GLUT proteins, the ‘‘sugar/polyol transport
signatures”, have been identiﬁed. The ﬁrst GLUT proteins were
cloned and characterized by their similarity to GLUT1 (GLUT1–
4), and are known as the ‘‘classical’’ GLUTs, with additional mem-
bers later identiﬁed through database mining and sequence ampli-
ﬁcation. In mammals, the sequence similarities among members of
the GLUT family range between 22% and 49% at the amino acid le-
vel. In addition to glucose, the GLUT proteins show a wide spec-
trum of ligands, including fructose, glucosamine, polyols like
myo-inositol and dehydroascorbate, and other small polar ligands
like ureate [16,17].
The gene coding for GLUT10, SLC2A10, was cloned as a candi-
date gene for type 2 diabetes in the Hsa20q13 susceptibility region
[18] and, independently, during the search for novel GLUT proteins
[19]. GLUT10 is a 541-amino acid protein with a predicted molec-
ular mass of 57 kDa [18]. Its hydropathic structure conforms to the
standard model of 12 transmembrane spans with a long exofacial
loop 9 of 90 amino acids, signiﬁcantly longer than the loops in
other GLUTs [18,19]. The protein sequence contains most of the su-
gar/polyol transporter signatures [16].
GLUT10 is most abundant in smooth muscle-rich organs [20],
consistent with its role in blood vessel architecture, and it is also
present in heart, liver, pancreas, and adipose [18,19,21]. When ex-
pressed in Xenopus oocytes, the standard assay for sugar transport,
human GLUT10 exhibited low-rate, saturable transport activity of
the non-metabolizable glucose analog, 2-[3H] -deoxy-D-glucose
(2-DOG) [18], with an apparent Km  0.3 mM, making it the GLUT
with the highest afﬁnity for glucose so far described [16]. Genetic
studies eventually demonstrated that SLC2A10 is not associated
with an increased susceptibility to type 2 diabetes [22].3. GLUT10 and ATS: the current model
The current model of GLUT10 function in the architectural
integrity of arterial walls was proposed by Coucke et al. in 2006
[7]. In the arterial wall of an ATS patient, an augmented Transform-
ing Growth Factor b (TGFb) activity was observed as indicated by
the increased levels of phosphorylated nuclear-translocated
SMAD2, a downstream effector of the TGFb signaling pathway. In-
creased expression of connective tissue growth factor, a TGFb-
dependent gene product, and down-regulation of decorin, an
inhibitor of TGFb signaling, were also detected [7]. In normal cells,
they were able to localize GLUT10 to the periphery of the cell nu-
cleus [7]. Based on these observations, Coucke et al. proposed that
GLUT10 is a transporter of glucose into the nucleus where, acting
as a gatekeeper, it would modulate the expression of glucose-
responsive genes, among them decorin [7]. Therefore, in the ab-
sence of functional GLUT10 in ATS, reduction of glucose transport
to the nucleus would result in the down-regulation of genes, such
as decorin, that in toto or in part are dependent on glucose for their
expression. Decreased levels of decorin, in turn, would result in thedisinhibition of the TGFb cascade eventually leading to the ob-
served high levels of phosphorylated SMAD2, Connective Tissue
Growth Factor (CTGF), and collagen [7].
In summary, the current model of GLUT10 function puts the dis-
regulation of the TGFb signaling pathway at the origin of the archi-
tectural defects in the arterial wall of ATS patients based on two
critical observations: (i) GLUT10 is a transporter of glucose; and,
(ii) GLUT10 is localized to the nuclear periphery. Our reinterpreta-
tion of the published data and our own preliminary observations
contradict the current model and puts forward a new hypothesis
for ATS etiology.4. Is GLUT10 a transporter of glucose?
In general terms, peripheral tissues are net users of glucose.
Glucose can be metabolized as a source of energy (e.g. in brain),
or ﬁrst converted into a storage molecule (glycogen) for later use
as fuel (e.g. in skeletal muscle). After internalization, free glucose
is quickly converted to glucose-6-phosphate (G6P), creating a steep
chemical gradient between the extracellular and intracellular com-
partments. Formation of G6P is catalyzed by a hexokinase, of which
four isoforms are known in mammals [23]. Most tissues present
hexokinase I, a high-afﬁnity enzyme inhibitable by its product,
G6P [23]. At physiological glucose concentrations (0.5–10 mM),
the kinetics of hexokinase I limits the intracellular glucose concen-
tration to 50% of its extracellular levels [24]. Small (<1 kDa) polar
molecules, like glucose, freely diffuse into the nucleus through the
nuclear pore and, therefore, do not require specialized transporters
to enter the nucleus [25]. Therefore, cytosolic and intranuclear glu-
cose levels equalize at steady-state levels of glucose [24]. The
necessity of a transporter of glucose in the nuclear periphery, as
proposed by Coucke et al. [7], is thus difﬁcult to envision. Addition-
ally, a high afﬁnity glucose transporter would make an extremely
unlikely modulator of glucose-dependent gene expression since,
at physiological glucose levels, GLUT10 would transport at maxi-
mum rate [18]. It is important to remember that the well-charac-
terized glucose sensor system in pancreatic beta cells that
modulates the secretion of insulin in response to glucose level in
the bloodstream uses the low-afﬁnity GLUT2 as transporter [16]
to ensure that changes in glucose concentration result in signiﬁ-
cant differences in the rate of translocation across the plasma
membrane.
Moreover, it is widely accepted that intranuclear glucose is not
the active metabolite in carbohydrate-dependent gene transcrip-
tion. Two transcriptional mechanisms have recently been eluci-
dated that transduce the glucose signal to the genome: the
Carbohydrate Response Element-Binding Protein (ChREBP) tran-
scription factor translocates from the cytosol to the nucleus in re-
sponse to glucose and upregulates hepatic glycolytic and lipogenic
genes [26]; and a number of transcription factors, including the
generalist Sp proteins, are modulated in their activities by the
addition of O-linked N-acetyl-glucosamine moieties generated by
the hexosamine pathway [27].
The previous discussion presupposes that GLUT10 is mainly a
transporter of glucose. The low rate of transport of the glucose ana-
log 2-DOG described by Dawson et al. [18] is signiﬁcantly lower
than shown by bona ﬁde glucose transporters [16]. In order to rep-
licate the functional assay, we injected frog oocytes with full-
length human GLUT10 mRNA and compared the uptake of radiola-
belled 2-DOG with that of oocytes injected with a human GLUT1
positive control RNA [28]. As shown in Supplementary Table 1,
GLUT10-injected oocytes failed to demonstrate a signiﬁcant uptake
of 2-DOG relative to control oocytes, whereas GLUT1-injected oo-
cytes showed an extremely signiﬁcant increase in 2-DOG uptake.
Whether from the inability of GLUT10 to appropriately localize to
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inability to transport glucose, questions should be raised on glu-
cose as the physiological ligand of GLUT10.Fig. 1. Model for the function of GLUT10 in the intracellular metabolism of ascorbic
acid. Vitamin C circulates in the bloodstream as two isoforms that differ in their5. Is GLUT10 located at the nuclear periphery?
Using a commercially available antibody against human
GLUT10, Coucke et al. found that in normal ﬁbroblast cells, GLUT10
localizes to the nuclear periphery [7]. We used transiently trans-
fected GLUT10-GFP constructs and organelle-speciﬁc ﬂuorescent
probes to image intracellular GLUT10. GFP-tagged GLUTs have
been previously reported as functional and to accurately represent
the distribution of the native proteins [29]. In PAC-1 rat aortic
smooth muscle cells, GLUT10-GFP ﬂuorescence was mostly seen
asymmetrically distributed in close proximity to the cell nucleus
(Supplementary Fig. 1A). When the cells were stained with ER-
Tracker Blue-White (Invitrogen), a ﬂuorescent dye for the Endo-
plasmic Reticulum (ER), the distribution of GLUT10-GFP over-
lapped with the ER-Tracker ﬂuorescence (Supplementary Fig. 1B
and C), suggesting that GLUT10 locates to the secretory pathway.
In no discernible way was GLUT10 found in association with the
nuclear envelope (Supplementary Fig. 1A and C).degree of oxidation: reduced ascorbic acid (AA) and oxidized dehydroascorbic acid
(DHAA). AA enters the cell through the sodium-dependent vitamin C antiporters,
and DHAA uses GLUT1, GLUT3 or GLUT4. Intracellular DHAA can be regenerated to
AA by cytosolic reductases. DHAA enters the ER using a hypothetical GLUT
transporter. We hypothesize that GLUT10 is the uncharacterized transporter of
DHAA. In the ER, DHAA is reduced to AA by the protein disulﬁde isomerase (PDI), a
subunit of prolyl hydroxylases. Prolyl- and lysyl-hydroxylases modify residues in
collagens and elastin that stabilize the mature molecules. In ATS, loss of GLUT10
would negatively affect the integrity of the deposited collagens and elastin, thus
weakening the ECM of connective tissues and inducing a TGFb response that
stimulates the proliferation of SMCs, and due to the anatomical constraints they are
subject to, leading to tortuosity of the arteries.6. GLUT10 and ascorbic acid: a hypothesis
Certain symptoms observed in ATS patients, such as laxity of
the skin and hyperextensibility of the joints, are also present in
a number of genetic syndromes of the collagen and elastin metab-
olisms [30,31]. In previous sections we showed that GLUT10
localizes to the ER, locus of the extensive post-translational modi-
ﬁcation of secreted proteins. To have a role in the secretory path-
way, a GLUT protein must be involved in the transport of a small
molecule essential for secretion. We propose that GLUT10 is a
transporter of ascorbic acid to the ER and that the primary defect
in ATS due to the absence of functional GLUT10 resides in the
assembly of abnormal collagens and/or elastin (Fig. 1).
Ascorbic Acid (AA), the reduced form of vitamin C, is a reducing
agent with antioxidant properties required as a cofactor in reac-
tions catalyzed by Cu+- and Fe2+-dependent oxygenases [32]. The
ER houses two types of enzymes that are AA-dependent and in-
volved in the synthesis of collagen and elastin: prolyl- and lysyl-
hydroxylases [30]. The former, that include the prolyl 3- and 4-
hydroxylases, modify certain proline residues of collagens, thus
stabilizing their triple helix region. Lower hydroxyproline caused
by the absence of AA, like in the nutritional disorder scurvy, lead
to lowered tensile strength of the collagenous matrix and mechan-
ical failure of connective tissues, among other effects [33]. Lysyl-
hydroxylases modify lysine residues of collagens and elastin to
serve as sites for intermolecular crosslinking in the assembly of
higher-order macromolecular complexes [30]. It is illustrative that
patients with Ehlers-Danlos VIA syndrome (OMIM 225400), with
mutations in the lysyl hydroxylase gene, PLOD1, show symptoms
common to ATS (cutis laxa, laxity of joints, micrognathia, and tor-
tuous retinal arteries) and an abnormally soluble collagen, likely
due to the loss of intermolecular crosslinks (OMIM 225400).
Vitamin C circulates in the bloodstream as reduced AA and its
oxidation product, Dehydroascorbic Acid (DHAA), which is not ac-
tive as cofactor [32]. To enter the cell, AA mainly uses the sodium-
dependent vitamin C transporters (SVCT1 and SVCT2) whereas
DHAA (and possibly also AA) traverses the plasma membrane using
GLUT1, GLUT3, or GLUT4 transporters [34]. Once inside the cell the
mechanism that vitamin C employs to reach the secretory pathway
is still uncharacterized, but it has been reported that DHAA trans-
locates to the ER using a transporter system with high afﬁnity and
low capacity, inhibitable by glucose transporter inhibitors, sug-gesting that translocation is mediated by a GLUT transporter
[35]. Intracisternal DHAA is then reduced back to AA by the protein
disulﬁde isomerase, the b subunit of the prolyl hydroxylase hetero-
trimers [36].
The idea that the primary defect in ATS resides in the synthesis
of abnormal collagens and/or elastin due to a deﬁciency in intracel-
lular vitamin C metabolism is supported by two important obser-
vations. First, it has been observed that the offspring of diabetic
mothers, both in humans and rodents, show a signiﬁcant increase
in the incidence of cardiovascular malformations [37–39] that
were reduced by supplementation of the maternal diet with vita-
min C [40]. Because DHAA and glucose compete for the GLUT pro-
teins that are able to transport both ligands [41], diabetic
hyperglycemia reduces the mobilization of AA to the developing
fetus [40] which show defects in neural crest-derived organs.
Micrognathia, pharyngeal arch artery defects, duplication and tel-
angiectasia of the aorta, persistent truncus arteriosus, and reduc-
tion of the thyroid gland are some of the most common defects
observed that are also present in ATS [37–39].
Second, in the AA-deﬁcient L-gulono-c-lactone oxidase (L-
GULO, the last enzyme in the AA biosynthetic pathway) null allele
mice (Gulo /), signiﬁcant abnormalities of the arterial walls
were observed [42]. Gulo / mice showed fragmentation of elas-
tic laminae, proliferation of SMCs, and increased deposition of
basement membrane materials, collagens and (abnormal) elastin
[42], reminiscent of ATS vascular histopathologies [8,9].
In the absence of GLUT10 (Fig. 1), reduction in the levels of AA/
DHAA in the ER intracisternal compartment would be expected to
lead to lowered prolyl- and lysyl-hydroxylase activities and, there-
fore, to a reduction in the number of hydroxyproline and hydroxy-
lysine residues in collagens and elastin. We believe that in the
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whereas outside the cardiovascular system, like the joints and skin,
the pathology probably reﬂects deposition of abnormal collagens.
This is supported by the experimental degradation of elastin or col-
lagen in dog carotids showing that elastase, but not collagenase,
led to decreased longitudinal retractive force that induced tortuos-
ity of the vessel [6]. Tortuosity is also observed in arterial segments
from mice hemizygous for the elastin gene (ELN +/) [43] and in
the ﬁbulin-5 KO animals, null for the matricellular protein that reg-
ulates deposition of elastic laminae [44].
In our model, upregulation of TGFb signaling is a secondary ef-
fect derived from the alteration in ECM structure from the deposi-
tion of abnormal components. Latent TGFb is present in the ECM
associated with microﬁbrils and becomes activated when damage
to the tissue releases protease enzymes that liberate active TGFb,
thus acting in what is essentially a sensor of ECM integrity [45]. Ac-
tive TGFb signaling, in turn, induces the expression of downstream
genes, like CTGF [7]. Additionally, TGFb is responsible for the re-
lease of active proteases, like elastases, that likely account for the
fragmentation of elastic laminae, as observed also in Marfan syn-
drome [46]. Finally, reduction of elastin deposition would activate
two responses to the compromised biomechanics of the vessel
wall: a switch in phenotype of the vascular SMCs from synthetic
to proliferative, with a concomitant increase in longitudinal exten-
sion and exacerbation of tortuosity, as seen in both the Gulo /
and ELN /mice [42,47]; and, secondly, a compensatory increase
in elastin synthesis with deposition of supernumerary elastic lam-
inae [43], as reported in the SLC2A10 mutant mice [48].
Our model predicts that, in SMCs derived from human patients
or mutant mice, uptake of DHAA into microsomal vesicles should
be reduced relative to normal cells. Collagen and elastin should
contain lower proportions of hydroxylated proline and lysine resi-
dues, with a concomitant decrease in the degree of crosslinking, as
indicated by lowered desmosine content in elastin. Upregulation of
TGFb signaling, nuclear translocation of phosphorylated SMAD2,
and overexpression of CTGF, have all been observed in ATS vessels
[7], and we should expect also an augmented activity of elastase
and proliferation rates of vascular SMCs. Our model may help ex-
plain why the GLUT10 mutant animal models so far described do
not fully mimic the human syndrome, especially the lack of arterial
tortuosity [48,49]. Rodents, unlike humans, are able to synthesize
AA and it is tempting to speculate that their developmental pro-
cesses may not suffer from what we can denominate ‘‘evolution-
ary” hypovitaminosis for vitamin C. If this is the case, rodent
development would be less susceptible to the loss of GLUT10.
We think that a double mutant of SLC2A10/Gulo should more accu-
rately reﬂect the human syndrome.
Acknowledgements
This work was supported by the Joseph and Josephine Rabino-
witz Award for Excellence in Research at the University of Pennsyl-
vania School of Dental Medicine.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2010.06.011.
References
[1] Jackson, Z.S., Dajnowiec, D., Gotlieb, A.I. and Langille, B.L. (2005) Partial off-
loading of longitudinal tension induces arterial tortuosity. Arterioscler.
Thromb. Vasc. Biol. 25, 957–962.
[2] Hademenos, G.J. and Massoud, T.F. (1997) Biophysical mechanisms of stroke.
Stroke 28, 2067–2077.[3] Wenn, C.M. and Newman, D.L. (1990) Arterial tortuosity. Australas. Phys. Eng.
Sci. Med. 13, 67–70.
[4] Cartwright, M.S., Hickling, W.H. and Roach, E.S. (2006) Ischemic stroke in an
adolescent with arterial tortuosity syndrome. Neurology 67, 360–361.
[5] Del Corso, L. et al. (1998) Tortuosity, kinking, and coiling of the carotid artery:
expression of atherosclerosis or aging? Angiology 49, 361–371.
[6] Dobrin, P.B., Schwarcz, T.H. and Baker, W.H. (1988) Mechanisms of arterial and
aneurysmal tortuosity. Surgery 104, 568–571.
[7] Coucke, P.J. et al. (2006) Mutations in the facilitative glucose transporter
GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat. Genet.
38, 452–457.
[8] Ertugrel, A. (1967) Diffuse tortuosity and lengthening of the arteries.
Circulation 36, 400–407.
[9] Wessels, M.W. et al. (2004) Three new families with arterial tortuosity
syndrome. Am. J. Med. Genet. A 131, 134–143.
[10] Gardella, R., Zoppi, N., Assanelli, D., Muiesan, M.L., Barlati, S. and Colombi, M.
(2004) Exclusion of candidate genes in a family with arterial tortuosity
syndrome. Am. J. Med. Genet. A 126A, 221–228.
[11] Callewaert, B.L. et al. (2008) Arterial tortuosity syndrome: clinical and
molecular ﬁndings in 12 newly identiﬁed families. Hum. Mutat. 29, 150–158.
[12] Coucke, P.J., Wessels, M.W., Van Acker, P., Gardella, R., Barlati, S., Willems, P.J.,
Colombi, M. and De Paepe, A. (2003) Homozygosity mapping of a gene for
arterial tortuosity syndrome to chromosome 20q13. J. Med. Genet. 40, 747–
751.
[13] Faiyaz-Ul-Haque, M. et al. (2008) Identiﬁcation of a p.Ser81Arg encoding
mutation in SLC2A10 gene of arterial tortuosity syndrome patients from 10
Qatari families. Clin. Genet. 74, 189–193.
[14] Franceschini, P., Guala, A., Licata, D., Di Cara, G. and Franceschini, D. (2000)
Arterial tortuosity syndrome. Am. J. Med. Genet. 91, 141–143.
[15] Akhurst, R.J. (2006) A sweet link between TGFBeta and vascular disease? Nat.
Genet. 38, 400–401.
[16] Manolescu, A.R., Witkowska, K., Kinnaird, A., Cessford, T. and Cheeseman, C.
(2007) Facilitated hexose transporters: new perspectives on form and
function. Physiology (Bethesda) 22, 234–240.
[17] Thorens, B. and Mueckler, M.M. (2010) Glucose transporters in the 21st
Century. Am. J. Physiol. Endocrinol. Metab. 298, E141–E145.
[18] Dawson, P.A., Mychaleckyj, J.C., Fossey, S.C., Mihic, S.J., Craddock, A.L. and
Bowden, D.W. (2001) Sequence and functional analysis of GLUT10: a glucose
transporter in the type 2 diabetes-linked region of chromosome 20q12–13.1.
Mol. Genet. Metab. 74, 186–199.
[19] McVie-Wylie, A.J., Lamson, D.R. and Chen, Y.T. (2001) Molecular cloning of a
novel member of the GLUT family of transporters, SLC2a10 (GLUT10),
localized on chromosome 20q13.1: a candidate gene for NIDDM
susceptibility. Genomics 72, 113–117.
[20] Wu, C. et al. (2009) BioGPS: an extensible and customizable portal for
querying and organizing gene annotation resources. Genome Biol. 10, R130.
[21] Wood, I.S., Hunter, L. and Trayhurn, P. (2003) Expression of class III facilitative
glucose transporter genes (GLUT-10 and GLUT-12) in mouse and human
adipose tissues. Biochem. Biophys. Res. Commun. 308, 43–49.
[22] Bento, J.L., Bowden, D.W., Mychaleckyj, J.C., Hirakawa, S., Rich, S.S., Freedman,
B.I. and Segade, F. (2005) Genetic analysis of the GLUT10 glucose transporter
(SLC2A10) polymorphisms in Caucasian American type 2 diabetes. BMC Med.
Genet. 6, 42.
[23] Wilson, J.E. (2003) Isozymes of mammalian hexokinase: structure, subcellular
localization and metabolic function. J. Exp. Biol. 206, 2049–2057.
[24] Fehr, M., Lalonde, S., Ehrhardt, D.W. and Frommer, W.B. (2004) Live imaging of
glucose homeostasis in nuclei of COS-7 cells. J. Fluoresc. 14, 603–609.
[25] Stehno-Bittel, L., Perez-Terzic, C. and Clapham, D.E. (1995) Diffusion across the
nuclear envelope inhibited by depletion of the nuclear Ca2+ store. Science 270,
1835–1838.
[26] Postic, C., Dentin, R., Denechaud, P.D. and Girard, J. (2007) ChREBP, a
transcriptional regulator of glucose and lipid metabolism. Annu. Rev. Nutr.
27, 179–192.
[27] Issad, T. and Kuo, M. (2008) O-GlcNAc modiﬁcation of transcription factors,
glucose sensing and glucotoxicity. Trends Endocrinol. Metab. 19, 380–389.
[28] Hruz, P.W. and Mueckler, M.M. (1999) Cysteine-scanning mutagenesis of
transmembrane segment 7 of the GLUT1 glucose transporter. J. Biol. Chem.
274, 36176–36180.
[29] Powell, K.A., Campbell, L.C., Tavare, J.M., Leader, D.P., Wakeﬁeld, J.A. and Gould,
G.W. (1999) Trafﬁcking of Glut4-green ﬂuorescent protein chimaeras in 3T3–
L1 adipocytes suggests distinct internalization mechanisms regulating cell
surface glut4 levels. Biochem. J. 344 (Pt 2), 535–543.
[30] Myllyharju, J. and Kivirikko, K.I. (2004) Collagens, modifying enzymes and
their mutations in humans, ﬂies and worms. Trends Genet. 20, 33–43.
[31] Kielty, C.M. (2006) Elastic ﬁbres in health and disease. Expert Rev. Mol. Med. 8,
1–23.
[32] Linster, C.L. and Van Schaftingen, E. (2007) Vitamin C, biosynthesis, recycling
and degradation in mammals. FEBS J. 274, 1–22.
[33] Englard, S. and Seifter, S. (1986) The biochemical functions of ascorbic acid.
Annu. Rev. Nutr. 6, 365–406.
[34] Liang, W.J., Johnson, D. and Jarvis, S.M. (2001) Vitamin C transport systems of
mammalian cells. Mol. Membr. Biol. 18, 87–95.
[35] Banhegyi, G., Marcolongo, P., Puskas, F., Fulceri, R., Mandl, J. and Benedetti, A.
(1998) Dehydroascorbate and ascorbate transport in rat liver microsomal
vesicles. J. Biol. Chem. 273, 2758–2762.
2994 F. Segade / FEBS Letters 584 (2010) 2990–2994[36] Nardai, G., Braun, L., Csala, M., Mile, V., Csermely, P., Benedetti, A.,
Mandl, J. and Banhegyi, G. (2001) Protein-disulﬁde isomerase- and
protein thiol-dependent dehydroascorbate reduction and ascorbate
accumulation in the lumen of the endoplasmic reticulum. J. Biol.
Chem. 276, 8825–8828.
[37] Siman, C.M., Gittenberger-De Groot, A.C., Wisse, B. and Eriksson, U.J. (2000)
Malformations in offspring of diabetic rats: morphometric analysis of neural
crest-derived organs and effects of maternal vitamin E treatment. Teratology
61, 355–367.
[38] Wren, C., Birrell, G. and Hawthorne, G. (2003) Cardiovascular malformations in
infants of diabetic mothers. Heart 89, 1217–1220.
[39] Molin, D.G., Roest, P.A., Nordstrand, H., Wisse, L.J., Poelmann, R.E., Eriksson, U.J.
and Gittenberger-De Groot, A.C. (2004) Disturbed morphogenesis of cardiac
outﬂow tract and increased rate of aortic arch anomalies in the offspring of
diabetic rats. Birth Defects Res. A Clin. Mol. Teratol. 70, 927–938.
[40] Siman, C.M. and Eriksson, U.J. (1997) Vitamin C supplementation of the
maternal diet reduces the rate of malformation in the offspring of diabetic
rats. Diabetologia 40, 1416–1424.
[41] Ngkeekwong, F.C. and Ng, L.L. (1997) Two distinct uptake mechanisms for
ascorbate and dehydroascorbate in human lymphoblasts and their interaction
with glucose. Biochem. J. 324 (Pt 1), 225–230.[42] Maeda, N., Hagihara, H., Nakata, Y., Hiller, S., Wilder, J. and Reddick, R. (2000)
Aortic wall damage in mice unable to synthesize ascorbic acid. Proc. Natl.
Acad. Sci. USA 97, 841–846.
[43] Wagenseil, J.E., Nerurkar, N.L., Knutsen, R.H., Okamoto, R.J., Li, D.Y. and
Mecham, R.P. (2005) Effects of elastin haploinsufﬁciency on the mechanical
behavior of mouse arteries. Am. J. Physiol. Heart Circ. Physiol. 289, H1209–
H1217.
[44] Nakamura, T. et al. (2002) Fibulin-5/DANCE is essential for elastogenesis
in vivo. Nature 415, 171–175.
[45] Annes, J.P., Munger, J.S. and Rifkin, D.B. (2003) Making sense of latent TGFbeta
activation. J. Cell Sci. 116, 217–224.
[46] Neptune, E.R. et al. (2003) Dysregulation of TGF-beta activation contributes to
pathogenesis in Marfan syndrome. Nat. Genet. 33, 407–411.
[47] Li, D.Y., Brooke, B., Davis, E.C., Mecham, R.P., Sorensen, L.K., Boak, B.B.,
Eichwald, E. and Keating, M.T. (1998) Elastin is an essential determinant of
arterial morphogenesis. Nature 393, 276–280.
[48] Cheng, C.H., Kikuchi, T., Chen, Y.H., Sabbagha, N.G., Lee, Y.C., Pan, H.J., Chang, C.
and Chen, Y.T. (2009) Mutations in the SLC2A10 gene cause arterial
abnormalities in mice. Cardiovasc. Res. 81, 381–388.
[49] Callewaert, B.L. et al. (2008) Absence of arterial phenotype in mice with
homozygous slc2A10 missense substitutions. Genesis 46, 385–389.
